ImmunityBio (IBRX) Total Debt Growth (5y) (2019 - 2026)
Powered by 
Analysis
ImmunityBio (IBRX) Total Debt Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | ImmunityBio | 8.45 Bn | 8.09 Bn | 50.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.54% |
| Mar 31, 2026 | 5.11% |
| Dec 31, 2025 | 3.82% |
| Sep 30, 2025 | 43.83% |
| Jun 30, 2025 | 167.83% |
| Mar 31, 2025 | 222.22% |
| Dec 31, 2024 | 257.65% |
| Sep 30, 2024 | 216.04% |
| Jun 30, 2024 | 207.55% |
| Mar 31, 2024 | 154.49% |
| Dec 31, 2023 | 146.84% |
| Sep 30, 2023 | 194.28% |
| Jun 30, 2023 | 205.67% |
| Mar 31, 2023 | 208.85% |
| Dec 31, 2022 | 183.84% |
| Sep 30, 2022 | 185.44% |
| Jun 30, 2022 | 208.26% |
| Mar 31, 2022 | 210.67% |
| Dec 31, 2021 | 222.29% |
| Sep 30, 2021 | 178.77% |